Editing Antidepressant (section)

===Pain===

====Fibromyalgia====
A 2012 [[meta-analysis]] concluded that antidepressant treatment favorably affects pain, health-related quality of life, depression, and sleep in [[fibromyalgia]] syndrome. [[Tricyclic antidepressant|Tricyclics]] appear to be the most effective class, with moderate effects on pain and sleep, and small effects on fatigue and health-related quality of life. The fraction of people experiencing a 30% pain reduction on tricyclics was 48%, versus 28% on placebo. For SSRIs and SNRIs, the fractions of people experiencing a 30% pain reduction were 36% (20% in the placebo comparator arms) and 42% (32% in the corresponding placebo comparator arms) respectively. Discontinuation of treatment due to side effects was common.<ref>{{cite journal|vauthors=Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C|s2cid=207301478|title=The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis|journal=CNS Drugs|volume=26|issue=4|pages=297–307|date=April 2012|pmid=22452526|doi=10.2165/11598970-000000000-00000}}</ref> Antidepressants including [[amitriptyline]], fluoxetine, duloxetine, [[milnacipran]], [[moclobemide]], and [[pirlindole]] are recommended by the European League Against Rheumatism (EULAR) for the treatment of fibromyalgia based on "limited evidence".<ref name="pmid17644548">{{cite journal|vauthors=Carville SF, Arendt-Nielsen L, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsøe B, Dincer F, Henriksson C, Henriksson KG, Kosek E, Longley K, McCarthy GM, Perrot S, Puszczewicz M, Sarzi-Puttini P, Silman A, Späth M, Choy EH|title=EULAR evidence-based recommendations for the management of fibromyalgia syndrome|journal=Annals of the Rheumatic Diseases|volume=67|issue=4|pages=536–541|date=April 2008|pmid=17644548|doi=10.1136/ard.2007.071522|s2cid=12121672|doi-access=free|hdl=2434/664614|hdl-access=free}}</ref>

====Neuropathic pain====
A 2014 meta-analysis from the [[Cochrane Collaboration]] found the antidepressant duloxetine to be effective for the treatment of pain resulting from [[diabetic neuropathy]].<ref>{{cite journal|vauthors=Lunn MP, Hughes RA, Wiffen PJ|title=Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia|journal=The Cochrane Database of Systematic Reviews|volume=1|issue=1|pages=CD007115|date=January 2014|pmid=24385423|doi=10.1002/14651858.CD007115.pub3|pmc=10711341}}</ref> The same group reviewed data for amitriptyline in the treatment of [[neuropathic pain]] and found limited useful randomized clinical trial data. They concluded that the long history of successful use in the community for the treatment of fibromyalgia and neuropathic pain justified its continued use.<ref name="Moore2015">{{cite journal|vauthors=Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ|title=Amitriptyline for neuropathic pain in adults|journal=The Cochrane Database of Systematic Reviews|issue=7|pages=CD008242|date=July 2015|volume=2015|pmid=26146793|pmc=6447238|doi=10.1002/14651858.CD008242.pub3}}</ref> The group was concerned about the potential overestimation of the amount of pain relief provided by amitriptyline, and highlighted that only a small number of people will experience significant pain relief by taking this medication.<ref name=Moore2015 />